(3-苄基-3-氮杂双环[4.1.0]庚-1-基)甲醇 | 309748-42-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (3-苄基-3-氮杂双环[4.1.0]庚-1-基)甲醇
• 英文名称: (3-benzyl-3-azabicyclo[4.1.0]heptan-1-yl)methanol
• 英文别名: (3-Benzyl-3-aza-bicyclor[4.1.0]hept-1-yl)-methanol；(3-Benzyl-3-aza-bicyclo[4.1.0]hept-1-yl)-methanol
• CAS: 309748-42-3
• 化学式: C₁₄H₁₉NO
• 分子量: 217.311
• InChiKey: HTLIMZCYFUKFSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3-苄基-3-氮杂双环[4.1.0]庚-1-基)甲醇 在 palladium 10% on activated carbon 、 氢气 、 戴斯-马丁氧化剂 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 50.0 ℃ 、7.0 MPa 条件下， 反应 48.0h， 生成 tert-Butyl 1-formyl-3-azabicyclo[4.1.0]heptane-3-carboxylate
  参考文献：
  名称：

  Synthesis of racemic and enantiopure 3,4-methanonipecotic acid

  摘要：

  The synthesis of both racemic and enantiomerically pure (1R,6S)-3,4-methanonipecotic acid, a cyclopropane-containing 8-amino acid, which is a valuable building block for drug discovery, is described. The synthetic scheme commences from natural (S)-malic acid and allows for the preparation of the title compound in 12 steps in 28% overall yield. A novel approach to the racemic 3,4-methanonipecotic acid, which relies on a Simmons-Smith cyclopropanation as the key step, was also developed. In this case, the product was obtained in 8 steps and 38% total yield. (C) 2015 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetasy.2015.09.015
• 作为产物：
  描述：

  3-吡啶甲醇 、 溴甲苯 在 diethylzinc 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 生成 (3-苄基-3-氮杂双环[4.1.0]庚-1-基)甲醇
  参考文献：
  名称：

  Synthesis of racemic and enantiopure 3,4-methanonipecotic acid

  摘要：

  The synthesis of both racemic and enantiomerically pure (1R,6S)-3,4-methanonipecotic acid, a cyclopropane-containing 8-amino acid, which is a valuable building block for drug discovery, is described. The synthetic scheme commences from natural (S)-malic acid and allows for the preparation of the title compound in 12 steps in 28% overall yield. A novel approach to the racemic 3,4-methanonipecotic acid, which relies on a Simmons-Smith cyclopropanation as the key step, was also developed. In this case, the product was obtained in 8 steps and 38% total yield. (C) 2015 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetasy.2015.09.015

文献信息

• Heterocyclic analgesic compounds and methods of use thereof
  申请人：——

  公开号：US20020016337A1

  公开（公告）日：2002-02-07

  One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

  本发明的一个方面涉及新颖的杂环化合物。本发明的第二个方面涉及将这些新颖的杂环化合物作为各种细胞受体的配体，包括阿片受体、其他G蛋白偶联受体和离子通道。本发明的另一个方面涉及将这些新颖的杂环化合物用作镇痛剂。
• BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS
  申请人：Pfizer Inc.

  公开号：EP3536685A1

  公开（公告）日：2019-09-11

  Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment of autoimmune and inflammatory diseases associated with Interleukin-1 Receptor Associated Kinase (IRAK), methods of synthesis, and intermediates are also disclosed.

  本发明公开了化合物、同系物和药学上可接受的盐，其中化合物具有式 Ia 的结构、 的结构。还公开了相应的药物组合物、与白细胞介素-1受体相关激酶（IRAK）相关的自身免疫性和炎症性疾病的治疗方法、合成方法和中间体。
• US6645980B1
  申请人：——

  公开号：US6645980B1

  公开（公告）日：2003-11-11
• US6677332B1
  申请人：——

  公开号：US6677332B1

  公开（公告）日：2004-01-13
• US6635661B2
  申请人：——

  公开号：US6635661B2

  公开（公告）日：2003-10-21